We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Alpha Cognition Inc. (ACOG - Free Report) shares ended the last trading session 8.6% higher at $5.96. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.
Alpha Cognition’s stock price rally is largely tied to the renewed investor optimism around its pipeline progress and the growth and expansion of its Alzheimer’s drug Zunveyl. The company is advancing multiple post-marketing studies to strengthen the real-world profile of Zunveyl. Enrollment is ongoing in the BEACON study, while the planned CONVERGE and RESOLVE studies aim to generate additional data on cognition, behavior, dosing, and tolerability in Alzheimer’s patients, particularly in long-term care settings. These efforts are expected to support future regulatory discussions and improve physician and payer confidence.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -15%. Revenues are expected to be $4.88 million, up 66.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Alpha Cognition Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACOG going forward to see if this recent jump can turn into more strength down the road.
Alpha Cognition Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU - Free Report) , another stock in the same industry, closed the last trading session 4.7% higher at $1.99. CRBU has returned 8% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Alpha Cognition Inc. (ACOG - Free Report) shares ended the last trading session 8.6% higher at $5.96. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.
Alpha Cognition’s stock price rally is largely tied to the renewed investor optimism around its pipeline progress and the growth and expansion of its Alzheimer’s drug Zunveyl. The company is advancing multiple post-marketing studies to strengthen the real-world profile of Zunveyl. Enrollment is ongoing in the BEACON study, while the planned CONVERGE and RESOLVE studies aim to generate additional data on cognition, behavior, dosing, and tolerability in Alzheimer’s patients, particularly in long-term care settings. These efforts are expected to support future regulatory discussions and improve physician and payer confidence.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -15%. Revenues are expected to be $4.88 million, up 66.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Alpha Cognition Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACOG going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Alpha Cognition Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU - Free Report) , another stock in the same industry, closed the last trading session 4.7% higher at $1.99. CRBU has returned 8% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).